Jie Ren1, Qiu-Chen Chen1, Feng Jin2, Hui-Zhe Wu1, Miao He1, Lin Zhao1, Zhao-Jin Yu1, Wei-Fan Yao1, Xiao-Yi Mi3, En-Hua Wang3, Min-Jie Wei1. 1. Department of Pharmacology, School of Pharmacy, China Medical University Shenyang, China. 2. Department of Surgical Oncology, The First Affiliated Hospital, China Medical University Shenyang, China. 3. Department of Pathology, College of Basic Medical Sciences, China Medical University Shenyang, Liaoning, China.
Abstract
AIM: The incidence of breast cancer in developing countries still increasing, to identify novel molecular markers associated with carcinogenesis and prognosis of breast cancer still being implemented. The largest subunit of Remodeling and spacing factor (RSF), Rsf-1, mediates ATPase-dependent chromatin remodeling. Its oncogenic properties have been demonstrated in certain carcinomas. The aim of this study was to examine the prognostic value of Rsf-1 in patients with primary breast carcinoma. METHODS: A total of 537 patients with primary breast cancer, and 54 with benign breast hyperplasia, were performed resection surgery in the same period were enrolled. Rsf-1 immunoexpression was retrospectively assessed by immunohistochemistry (IHC). As well as, it relationship with clinicopathological factors and patient survival (LRFS, DFS and OS) was investigated. RESULTS: Compared with benign breast hyperplasia tissues, higher percentage of Rsf-1 positive expression was detected in malignant breast carcinomas. Based on IHC staining extent × intensity scores and ROC analysis, 278 of 526 cancers (52.9%) had high-expression (cut-off values 2.5) of Rsf-1, which correlated significantly to pathologic subtypes of breast cancer (DCIS vs. IDC, P < 0.001; ILC vs. IDC, P = 0.036), bigger tumor size (P = 0.030), higher TNM stage (P = 0.044), and p53-positive expression. In addition, there was a trend that high-expression of Rsf-1 associated with younger age (P = 0.053). We further prove that combined positive-expression of Rsf-1 and p53 (Rsf-1 (+)/p53 (+)) was correlated with the bigger tumor size (P = 0.018), and higher TNM stage (P = 0.024). Kaplan-Meier survival analysis showed that Rsf-1 high-expression and combined positive-expression of Rsf-1 and p53 (Rsf-1 (+)/p53 (+)) exhibited a significant correlation with poor overall survival of patients with primary breast cancer, and no association has been identified in relation to LRFS or DFS. Especially, Univariate and multivariate survival analysis demonstrated Rsf-1 expression is an independent prognostic parameter for the overall survival of patients with breast cancer. CONCLUSIONS: High-expression of Rsf-1 is associated with pathologic subtypes of breast cancer, aggressive phenotype, p53 positive and poor clinical outcome, which confers tumor aggressiveness through chromatin remodeling, and targeting Rsf-1 gene and the pathway it related may provide new therapeutic avenues for treating breast cancer.
AIM: The incidence of breast cancer in developing countries still increasing, to identify novel molecular markers associated with carcinogenesis and prognosis of breast cancer still being implemented. The largest subunit of Remodeling and spacing factor (RSF), Rsf-1, mediates ATPase-dependent chromatin remodeling. Its oncogenic properties have been demonstrated in certain carcinomas. The aim of this study was to examine the prognostic value of Rsf-1 in patients with primary breast carcinoma. METHODS: A total of 537 patients with primary breast cancer, and 54 with benign breast hyperplasia, were performed resection surgery in the same period were enrolled. Rsf-1 immunoexpression was retrospectively assessed by immunohistochemistry (IHC). As well as, it relationship with clinicopathological factors and patient survival (LRFS, DFS and OS) was investigated. RESULTS: Compared with benign breast hyperplasia tissues, higher percentage of Rsf-1 positive expression was detected in malignant breast carcinomas. Based on IHC staining extent × intensity scores and ROC analysis, 278 of 526 cancers (52.9%) had high-expression (cut-off values 2.5) of Rsf-1, which correlated significantly to pathologic subtypes of breast cancer (DCIS vs. IDC, P < 0.001; ILC vs. IDC, P = 0.036), bigger tumor size (P = 0.030), higher TNM stage (P = 0.044), and p53-positive expression. In addition, there was a trend that high-expression of Rsf-1 associated with younger age (P = 0.053). We further prove that combined positive-expression of Rsf-1 and p53 (Rsf-1 (+)/p53 (+)) was correlated with the bigger tumor size (P = 0.018), and higher TNM stage (P = 0.024). Kaplan-Meier survival analysis showed that Rsf-1 high-expression and combined positive-expression of Rsf-1 and p53 (Rsf-1 (+)/p53 (+)) exhibited a significant correlation with poor overall survival of patients with primary breast cancer, and no association has been identified in relation to LRFS or DFS. Especially, Univariate and multivariate survival analysis demonstrated Rsf-1 expression is an independent prognostic parameter for the overall survival of patients with breast cancer. CONCLUSIONS: High-expression of Rsf-1 is associated with pathologic subtypes of breast cancer, aggressive phenotype, p53 positive and poor clinical outcome, which confers tumor aggressiveness through chromatin remodeling, and targeting Rsf-1 gene and the pathway it related may provide new therapeutic avenues for treating breast cancer.
Entities:
Keywords:
Rsf-1; breast cancer; chromatin remodeling; p53; prognosis
Authors: R Soong; P D Robbins; B R Dix; F Grieu; B Lim; S Knowles; K E Williams; G R Turbett; A K House; B J Iacopetta Journal: Hum Pathol Date: 1996-10 Impact factor: 3.466
Authors: R C Bast; P Ravdin; D F Hayes; S Bates; H Fritsche; J M Jessup; N Kemeny; G Y Locker; R G Mennel; M R Somerfield Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Luke Hughes-Davies; David Huntsman; Margarida Ruas; Francois Fuks; Jacqueline Bye; Suet-Feung Chin; Jonathon Milner; Lindsay A Brown; Forrest Hsu; Blake Gilks; Torsten Nielsen; Michael Schulzer; Stephen Chia; Joseph Ragaz; Anthony Cahn; Lori Linger; Hilal Ozdag; Elena Cattaneo; E S Jordanova; Edward Schuuring; David S Yu; Ashok Venkitaraman; Bruce Ponder; Aidan Doherty; Samuel Aparicio; David Bentley; Charles Theillet; Chris P Ponting; Carlos Caldas; Tony Kouzarides Journal: Cell Date: 2003-11-26 Impact factor: 41.582
Authors: Charlotte Es Hoogstins; Benjamin Weixler; Leonora Sf Boogerd; Diederik J Hoppener; Hendrica Ajm Prevoo; Cornelis Fm Sier; Jacobus Wa Burger; Cornelis Verhoef; Shadvhi Bhairosingh; Arantza Farina Sarasqueta; Jacobus Burggraaf; Alexander L Vahrmeijer Journal: Biomark Cancer Date: 2017-08-28